Alkermes, Inc. is an integrated biotechnology company. The company is engaged in the business of developing, manufacturing, and commercializing medicines for the treatment of prevalent, chronic diseases. Alkermes, Inc. develops, manufactures, and commercializes VIVITROL for alcohol dependence and manufactures RISPERDAL CONSTA for schizophrenia and bipolar I disorder. Its pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system (CNS) disorders, reward disorders, addiction, diabetes, and autoimmune disorders. The company has a research facility in Massachusetts and a commercial manufacturing facility in Ohio. RISPERDAL CONSTA is used for the treatment of schizophrenia and for the treatment of bipolar I disorder. VIVITROL is an extended-release MEDISORB formulation of naltrexone, as a once-monthly injectable medication for the treatment of alcohol dependence.